IN2014DN09584A - - Google Patents
Info
- Publication number
- IN2014DN09584A IN2014DN09584A IN9584DEN2014A IN2014DN09584A IN 2014DN09584 A IN2014DN09584 A IN 2014DN09584A IN 9584DEN2014 A IN9584DEN2014 A IN 9584DEN2014A IN 2014DN09584 A IN2014DN09584 A IN 2014DN09584A
- Authority
- IN
- India
- Prior art keywords
- treatment
- neurologic disorders
- pantothenate
- compounds
- present disclosure
- Prior art date
Links
- 208000012902 Nervous system disease Diseases 0.000 abstract 2
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical class OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 abstract 1
- 102100024127 Pantothenate kinase 2, mitochondrial Human genes 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 208000002593 pantothenate kinase-associated neurodegeneration Diseases 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
- A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/06—Phosphorus compounds without P—C bonds
- C07F9/22—Amides of acids of phosphorus
- C07F9/24—Esteramides
- C07F9/2404—Esteramides the ester moiety containing a substituent or a structure which is considered as characteristic
- C07F9/242—Esteramides the ester moiety containing a substituent or a structure which is considered as characteristic of hydroxyaryl compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/06—Phosphorus compounds without P—C bonds
- C07F9/22—Amides of acids of phosphorus
- C07F9/222—Amides of phosphoric acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/06—Phosphorus compounds without P—C bonds
- C07F9/22—Amides of acids of phosphorus
- C07F9/24—Esteramides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/06—Phosphorus compounds without P—C bonds
- C07F9/22—Amides of acids of phosphorus
- C07F9/24—Esteramides
- C07F9/2454—Esteramides the amide moiety containing a substituent or a structure which is considered as characteristic
- C07F9/2458—Esteramides the amide moiety containing a substituent or a structure which is considered as characteristic of aliphatic amines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
- C07F9/572—Five-membered rings
- C07F9/5728—Five-membered rings condensed with carbocyclic rings or carbocyclic ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/06—Phosphorus compounds without P—C bonds
- C07F9/08—Esters of oxyacids of phosphorus
- C07F9/09—Esters of phosphoric acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
- C07F9/65616—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings containing the ring system having three or more than three double bonds between ring members or between ring members and non-ring members, e.g. purine or analogs
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Psychology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Enzymes And Modification Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261639602P | 2012-04-27 | 2012-04-27 | |
| PCT/US2013/038458 WO2013163576A1 (en) | 2012-04-27 | 2013-04-26 | Pantothenate derivatives for the treatment of neurologic disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IN2014DN09584A true IN2014DN09584A (enrdf_load_html_response) | 2015-07-17 |
Family
ID=48428654
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IN9584DEN2014 IN2014DN09584A (enrdf_load_html_response) | 2012-04-27 | 2013-04-26 |
Country Status (24)
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2013251345B2 (en) * | 2012-04-27 | 2017-08-31 | Retrophin, Inc. | Pantothenate derivatives for the treatment of neurologic disorders |
| ES2701531T3 (es) | 2013-10-25 | 2019-02-22 | Retrophin Inc | Derivados de pantotenato para el tratamiento de trastornos neurológicos |
| EP2868662A1 (en) * | 2013-11-04 | 2015-05-06 | Acies Bio d.o.o. | Stable pantetheine derivatives for the treatment of pantothenate kinase associated neurodegeneration (pkan) and methods for the synthesis of such compounds |
| MX2018006636A (es) | 2015-12-08 | 2018-08-15 | Retrophin Inc | Fosfatos ciclicos y fosforoamidatos ciclicos para el tratamiento de trastornos neurologicos. |
| SG11201906811WA (en) * | 2017-02-07 | 2019-08-27 | Retrophin Inc | Solid fosmetpantotenate formulations |
| US12065404B2 (en) | 2022-03-18 | 2024-08-20 | Enveric Biosciences Canada Inc. | C4-carboxylic acid-substituted tryptamine derivatives and methods of using |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2676976A (en) | 1950-12-04 | 1954-04-27 | Nat Res Dev | Synthesis of pantothenic acid-4' phosphate |
| US2870188A (en) | 1955-10-03 | 1959-01-20 | Hoffmann La Roche | Process for the manufacture of pantothenic acid 4'-phosphate and its salts |
| RU2002110463A (ru) * | 1999-09-21 | 2004-02-27 | Басф Акциенгезелльшафт (De) | Способ и микроорганизмы для получения пантосоединений |
| WO2003008626A2 (en) | 2001-07-20 | 2003-01-30 | Oregon Health And Science University | Novel human nucleic acids encoding a pantothenate kinase and methods of use |
| AU2002316575A1 (en) * | 2002-07-03 | 2004-01-23 | Basf Aktiengesellschaft | Microorganisms and processes for enhanced production of pantothenate |
| JP2009504704A (ja) * | 2005-08-15 | 2009-02-05 | エフ．ホフマン−ラ ロシュ アーゲー | 抗ウイルス４′−置換プロヌクレオチドホスホルアミダート |
| AU2013251345B2 (en) * | 2012-04-27 | 2017-08-31 | Retrophin, Inc. | Pantothenate derivatives for the treatment of neurologic disorders |
-
2013
- 2013-04-26 AU AU2013251345A patent/AU2013251345B2/en not_active Ceased
- 2013-04-26 PL PL13722201T patent/PL2841438T3/pl unknown
- 2013-04-26 PT PT16001739T patent/PT3112372T/pt unknown
- 2013-04-26 PT PT137222014T patent/PT2841438T/pt unknown
- 2013-04-26 RS RS20160939A patent/RS55319B1/sr unknown
- 2013-04-26 DK DK13722201.4T patent/DK2841438T3/en active
- 2013-04-26 PL PL16001739T patent/PL3112372T3/pl unknown
- 2013-04-26 RS RS20190049A patent/RS58336B1/sr unknown
- 2013-04-26 SM SM20190007T patent/SMT201900007T1/it unknown
- 2013-04-26 JP JP2015509192A patent/JP6254151B2/ja not_active Expired - Fee Related
- 2013-04-26 ES ES13722201.4T patent/ES2600179T3/es active Active
- 2013-04-26 KR KR20147033141A patent/KR20150035550A/ko not_active Abandoned
- 2013-04-26 LT LTEP13722201.4T patent/LT2841438T/lt unknown
- 2013-04-26 US US13/871,691 patent/US8673883B2/en not_active Expired - Fee Related
- 2013-04-26 CN CN201611221824.7A patent/CN106977544B/zh not_active Expired - Fee Related
- 2013-04-26 EP EP16001739.8A patent/EP3112372B1/en active Active
- 2013-04-26 RU RU2014147739A patent/RU2653497C2/ru not_active IP Right Cessation
- 2013-04-26 EP EP13722201.4A patent/EP2841438B1/en active Active
- 2013-04-26 BR BR112014026817A patent/BR112014026817A2/pt not_active Application Discontinuation
- 2013-04-26 ES ES16001739T patent/ES2708813T3/es active Active
- 2013-04-26 SI SI201330307A patent/SI2841438T1/sl unknown
- 2013-04-26 RU RU2018112720A patent/RU2018112720A/ru not_active Application Discontinuation
- 2013-04-26 WO PCT/US2013/038458 patent/WO2013163576A1/en active Application Filing
- 2013-04-26 MX MX2014013048A patent/MX360149B/es active IP Right Grant
- 2013-04-26 HR HRP20161389TT patent/HRP20161389T1/hr unknown
- 2013-04-26 CA CA2879314A patent/CA2879314A1/en not_active Abandoned
- 2013-04-26 DK DK16001739.8T patent/DK3112372T3/en active
- 2013-04-26 SI SI201331263T patent/SI3112372T1/sl unknown
- 2013-04-26 HU HUE13722201A patent/HUE029474T2/en unknown
- 2013-04-26 IN IN9584DEN2014 patent/IN2014DN09584A/en unknown
- 2013-04-26 EP EP18201414.2A patent/EP3489248A1/en not_active Withdrawn
- 2013-04-26 TR TR2018/19263T patent/TR201819263T4/tr unknown
- 2013-04-26 LT LTEP16001739.8T patent/LT3112372T/lt unknown
- 2013-04-26 HU HUE16001739A patent/HUE042199T2/hu unknown
- 2013-04-26 CN CN201380033271.0A patent/CN104520307B/zh not_active Expired - Fee Related
-
2014
- 2014-01-16 US US14/157,173 patent/US9181286B2/en not_active Expired - Fee Related
-
2015
- 2015-09-30 US US14/871,450 patent/US9629862B2/en not_active Expired - Fee Related
-
2016
- 2016-11-03 SM SM201600395T patent/SMT201600395B/it unknown
- 2016-11-04 CY CY20161101130T patent/CY1118198T1/el unknown
-
2017
- 2017-03-22 JP JP2017055792A patent/JP6560284B2/ja not_active Expired - Fee Related
- 2017-10-04 AU AU2017239508A patent/AU2017239508C1/en not_active Ceased
-
2019
- 2019-01-04 HR HRP20190038TT patent/HRP20190038T1/hr unknown
- 2019-02-05 CY CY20191100156T patent/CY1121238T1/el unknown
- 2019-07-18 JP JP2019132651A patent/JP2019206553A/ja active Pending
- 2019-08-20 AU AU2019219733A patent/AU2019219733A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12016500953A1 (en) | Tricyclic compounds as anticancer agents | |
| MX2013005549A (es) | Aminas heterociclicas y sus usos. | |
| TN2015000278A1 (en) | Autotaxin inhibitors | |
| MX2016002544A (es) | Compuestos utiles como inmunomoduladores. | |
| PH12013502565A1 (en) | Substituted imidazopyridinyl-aminopyridine compounds | |
| PH12016500094A1 (en) | Autotaxin inhibitors | |
| MX365294B (es) | Inhibidores de proteína cinasa dependiente de adn. | |
| GB201106743D0 (en) | Novel compounds | |
| NZ700928A (en) | Dna-pk inhibitors | |
| MY188363A (en) | Substituted tricyclic compounds as fgfr inhibitors | |
| NZ628294A (en) | Compositions and methods of use of phorbol esters for the treatment of stroke | |
| IN2014DN06104A (enrdf_load_html_response) | ||
| MY181602A (en) | Isochromene derivatives as phosphoinositide 3-kinases inhibitors | |
| PH12014501967A1 (en) | Benzodioxanes in combination with other actives for inhibiting leukotriene production | |
| MX2016004540A (es) | Tiazolopirimidinonas como moduladores de la actividad de receptores de n-metil-d-aspartato (nmda). | |
| IN2014DN09584A (enrdf_load_html_response) | ||
| IN2015DN00085A (enrdf_load_html_response) | ||
| MX2014004210A (es) | Derivados de 2-oxo-piperidinilo. | |
| GB201209015D0 (en) | Novel compounds | |
| MX2016002930A (es) | Moduladores del receptor x hepatico (lxr). | |
| UA117567C2 (uk) | Композиція, яка стимулює лактацію, на основі фосфатидилсерину | |
| NZ629475A (en) | Pharmaceutical composition comprising benzyl alcohol for the treatment of migraines | |
| MY184721A (en) | Use of odiparcil in the treatment of a mucopolysaccharidosis | |
| PH12016502133A1 (en) | Substituted tricycle compounds as fgfr inhibitors |